Oncology Medical News about Epigenetic Inactivation

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Epigenetic Inactivation of the Circadian Clock Gene BMAL1 in Hematologic Malignancies
Cancer Research, 11/03/09

Taniguchi H et al. – The DNA hypermethylation–associated loss of BMAL1 also prevents the recruitment of its natural partner, the CLOCK protein, to their common targets, further enhancing the perturbed circadian rhythm of the malignant cells. These findings suggest that BMAL1 epigenetic inactivation contributes to the development of hematologic malignancies by disrupting the cellular circadian clock.

<< Previous
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol...

Next >>
Thrombin generation assay as a possible tool for assessment of...

Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies
Cancer Research, 11/03/09 Relevance Score: 64%

The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia
European Journal of Haematology, 10/14/09 Relevance Score: 64%

Increased microsatellite instability and epigenetic inactivation of the hMLH1 gene in head and neck squamous cell carcinoma
Otolaryngology Head and Neck Surgery, 10/09/09 Relevance Score: 64%

Epigenetic mechanisms in the development of type 2 diabetes
Trends in Endocrinology and Metabolism, 11/03/09 Relevance Score: 45%

Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies
The Lancet Neurology, 10/21/09 Relevance Score: 43%